Alzheimer's Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

  • ID: 3646820
  • Report
  • Region: Asia Pacific
  • 151 pages
  • GBI Research
1 of 4
Alzheimer’s Disease Market in Asia-Pacific to Surpass $5 Billion by 2021
Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies

Summary

Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there are only seven repositioned drugs and five generic drugs. This shows progression in terms of the different molecules being developed as therapeutic agents within the AD pipeline.

Scope

The AD market has a lack of therapeutic options.
- Which classes of drug dominate the market?
- What newly approved therapies have entered the market?
- How do the leading marketed therapies compare clinically?
- How will the new therapies be positioned in the treatment of AD?
- How have selected late-stage pipeline therapies performed in clinical trials?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
AD clinical trials have an overall attrition rate of 94%.
- What are the failure rates for individual Phases of clinical development?
- How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?
The AD market is forecast to rise from a value of $3 billion in 2014 to $5.1 billion in 2021, at a CAGR of 7.9% across the four Asia-Pacific markets assessed.
- How much of a role will disease prevalence and new product approvals play in market growth?
- Will generic competition have a significant impact on the market over the forecast period?
There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.
- Which territories show the most deal activity?
- What were the trends in deal completion by product stage of development?
- What were the conditions of the key licensing or co-development deals to take place in AD?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
- Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
- Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size in four Asia-Pacific markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Options
2.8.1 Treatment Algorithm
2.8.2 Pharmacological Treatments
2.8.3 Non-pharmacological Treatments
3 Marketed Products
3.1 Overview
3.2 Acetylcholinesterase Inhibitors
3.2.1 Aricept (donepezil) - Eisai
3.2.2 Exelon (rivastigmine) - Novartis
3.2.3 Razadyne (galantamine) - Janssen
3.2.4 Cognex (tacrine) - Shionogi
3.3 NMDA Receptor Antagonists
3.3.1 Namenda/Ebixa/Axura/Abixa (Memantine), Merz/Lundbeck/Forest/Daiichi Sankyo
3.4 AChEI and NMDA Receptor Antagonists
3.4.1 Namzaric (memantine ER + donepezil), Actavis and Adamas
3.5 Heat Map - Marketed Products Overview
4 Pipeline Analysis
4.1 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.2 Pipeline Analysis by Mechanism of Action
4.3 Promising Pipeline Candidates
4.3.1 MK-8931- Merck
4.3.2 LMTX (methylthioninium chloride) - TauRX Therapeutics
4.3.3 Gantenerumab (RG-1540) - Roche
4.3.4 AZD3293 - AstraZeneca
4.3.5 AB1010 (masitinib) - AB Science
4.3.6 BIIB037 - Biogen
4.3.7 TTP488 - vTv Therapeutics
4.3.8 EVP-6124 - FORUM Pharmaceuticals
4.3.9 Lu AE58054 - Lundbeck
4.3.10 Sodium Oligomannurarate
4.4 Heat Map for Pipeline Products
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target
5.2.2 Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Stage of Development and Molecule Type
5.3.2 Trial Duration by Stage of Development and Molecular Target
5.4 Summary of Clinical Trial Metrics
6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Japan
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
7 Drivers and Barriers
7.1 Drivers
7.1.1 Rising Prevalence
7.1.2 Increasing Healthcare Reforms for Elderly Population
7.1.3 Increasing Health Insurance Coverage for Aged Population
7.1.4 Increasing Public and Policy-Maker Awareness
7.1.5 Greater Focus on Prodromal and Presymptomatic AD
7.2 Barriers
7.2.1 High Rate of Clinical Trial Failure
7.2.2 Impending Patent Cliffs and Generic Erosion
7.2.3 Drug Testing in Patients with Established AD and Advanced Neurodegeneration
7.2.4 Low Diagnosis and Treatment Rate
7.2.5 Additional Competition from Traditional Medicines
8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals
9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.2 Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: AD Market, Symptoms of AD at Different Stages of Disease
Table 2: AD Market, Symptoms of Mid Cognitive Impairment
Table 3: AD Market, Mini Mental State Exam
Table 4: AD Market, Alzheimer’s Disease Assessment Scale Cognitive Subscale
Table 5: AD Market, Mild Cognitive Impairment Diagnosis Guidelines
Table 6: AD Market, Global Deterioration Scale for AD
Table 7: AD Market, Management of AD Symptoms
Table 8: AD Market, Global, Pipeline Products, Discovery, 2016
Table 9: AD Market, Global, Pipeline Products, Preclinical, 2016
Table 10: AD Market, Global, Pipeline Products, Phase I, 2016
Table 11: AD Market, Global, Pipeline Products, Phase II, 2016
Table 12: AD Market, Global, Pipeline Products, Phase III, 2016
Table 13: MCI Market, Asia-Pacific, Market Forecast, 2014-2021
Table 14: AD Market, Asia-Pacific, Market Forecast, 2014-2021
Table 15: AD and MCI Combined Market, Asia-Pacific, Market Forecast, 2014-2021
Table 16: MCI Market, India, Market Forecast, 2014-2021
Table 17: AD Market, India, Market Forecast, 2014-2021
Table 18: AD and MCI Combined Market, India, Market Forecast, 2014-2021
Table 19: MCI Market, China, Market Forecast, 2014-2021
Table 20: AD Market, China, Market Forecast, 2014-2021
Table 21: AD and MCI Combined Market, China, Market Forecast, 2014-2021
Table 22: MCI Market, Australia, Market Forecast, 2014-2021
Table 23: AD Market, Australia, Market Forecast, 2014-2021
Table 24: AD and MCI Combined Market, Australia, Market Forecast, 2014-2021
Table 25: MCI Market, Japan, Market Forecast, 2014-2021
Table 26: AD Market, Japan, Market Forecast, 2014-2021
Table 27: MCI and AD Combined Market, Japan, Market Forecast, 2014-2021

1.2 List of Figures
Figure 1: AD Market, Treatment Algorithm of AD
Figure 2: AD Market, Heat Map for Marketed Products
Figure 3: AD Market, Overall Pipeline
Figure 4: AD Market, Pipeline by Mechanism of Action (%)
Figure 5: AD Market, Asia-Pacific, Verubecestat Market Forecast ($m), 2020-2021
Figure 6: AD Market, Asia-Pacific, LMTX Market Forecast ($m), 2018-2021
Figure 7: AD Market, Asia-Pacific, Gantenerumab Market Forecast ($m), 2020-2021
Figure 8: AD Market, Heat Map for Pipeline Products
Figure 9: AD Market, Clinical Trial Failure Rates by Phase (%)
Figure 10: AD Market, Clinical Trial Failure Rates by Molecular Target (%)
Figure 11: AD Market, Clinical Trial Size per Product by Molecule Type (participants)
Figure 12: AD Market, Clinical Trial Size per Product by Molecular Target (participants)
Figure 13: AD Market, Clinical Trial Size per Trial by Molecule Type (participants)
Figure 14: AD Market, Clinical Trial Size per Trial by Molecular Target (participants)
Figure 15: AD Market, Clinical Trial Duration by Molecule Type (months)
Figure 16: AD Market, Clinical Trial Duration by Molecular Target (months)
Figure 17: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 18: AD Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 19: AD and MCI Market, Asia-Pacific, Treatment Patterns (million), 2014-2021
Figure 20: AD and MCI Combined Market, Asia-Pacific, Treatment Patterns (million), 2014-2021
Figure 21: AD and MCI Market, Asia-Pacific, Market Size ($bn), 2014-2021
Figure 22: AD and MCI Combined Market, Asia-Pacific, Market Size ($bn), 2014-2021
Figure 23: AD and MCI Market, India, Treatment Patterns (million), 2014-2021
Figure 24: AD and MCI Combined Market, India, Treatment Patterns (million), 2014-2021
Figure 25: AD and MCI Market, India, Annual Cost of Therapy ($), 2014-2021
Figure 26: AD and MCI Market, India, Market Size ($m), 2014-2021
Figure 27: AD and MCI Combined Market, India, Market Size ($m), 2014-2021
Figure 28: AD and MCI Market, China, Treatment Patterns (million), 2014-2021
Figure 29: AD and MCI Combined Market, China, Treatment Patterns (million), 2014-2021
Figure 30: AD and MCI Market, China, Annual Cost of Therapy ($), 2014-2021
Figure 31: AD and MCI Market, China, Market Size ($m), 2014-2021
Figure 32: AD and MCI Combined Market, China, Market Size ($m), 2014-2021
Figure 33: AD and MCI Market, Australia, Treatment Patterns (‘000), 2014-2021
Figure 34: AD and MCI Combined Market, Australia, Treatment Patterns (‘000), 2014-2021
Figure 35: AD and MCI Market, Australia, Annual Cost of Therapy ($), 2014-2021
Figure 36: AD and MCI Market, Australia, Market Size ($m), 2014-2021
Figure 37: AD and MCI Combined Market, Australia, Market Size ($m), 2014-2021
Figure 38: AD and MCI Market, Japan, Treatment Patterns (million), 2014-2021
Figure 39: AD and MCI Combined Market, Japan, Treatment Patterns (million), 2014-2021
Figure 40: AD and MCI Market, Japan, Annual Cost of Therapy ($), 2014-2021
Figure 41: AD and MCI Market, Japan, Market Size ($m), 2014-2021
Figure 42: AD and MCI Combined Market, Japan, Market Size ($bn), 2014-2021
Figure 43: AD Market, Licensing Deals by Value, 2006-2015
Figure 44: AD Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
Figure 45: AD Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015
Figure 46: AD Market, Global, Licensing Deals by Molecule Type and Value, 2006-2015
Figure 47: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015
Figure 48: AD Market, Global, Co-development Deals by Value, 2006-2015
Figure 49: AD Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2015
Figure 50: AD Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2015
Figure 51: AD Market, Global, Co-development Deals by Molecule Type and Value, 2006-2015
Figure 52: AD Market, Global, Licensing Deals by Molecular Target and Aggregate Value, 2006-2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll